At the halfway point of the process, the Company received notice from the FDA that additional information regarding the PMA is required for the continuation of a substantive review. This request, which is not unique to the Breakthrough Device Program, places the application file on hold for approximately 4 to 6 months while the Company addresses the FDA's questions.
any thoughts on what a substantive review would mean?
also what does the context of "not unique" imply?
thanks
At the halfway point of the process, the Company received notice...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.50 |
Change
-0.150(4.11%) |
Mkt cap ! $244.5M | |||
| Open | High | Low | Value | Volume |
| $3.79 | $3.85 | $3.32 | $3.375M | 944.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $3.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.53 | 19524 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |